| Followers | 24 |
| Posts | 2408 |
| Boards Moderated | 0 |
| Alias Born | 04/12/2006 |
Tuesday, June 02, 2020 10:47:17 PM
Item 7.01 Regulation FD Disclosures.
On June 1, 2020, Biomerica, Inc. (“Biomerica”) issued a press release announcing that it had signed agreements with Mayo Clinic to join its clinical trial for its InFoods product. It also announced that it had received a patent in Japan pertaining to its Infoods product. A copy of Biomerica’s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.
The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
On June 1, 2020, Biomerica, Inc. (“Biomerica”) issued a press release announcing that it had signed agreements with Mayo Clinic to join its clinical trial for its InFoods product. It also announced that it had received a patent in Japan pertaining to its Infoods product. A copy of Biomerica’s press release is furnished hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated in this Item 7.01 in its entirety.
The information contained in Item 7.01 of this Current Report on Form 8-K, including the exhibit attached hereto, is being furnished and shall not be deemed to be “filed” for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Recent BMRA News
- Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development • GlobeNewswire Inc. • 05/28/2026 12:19:00 PM
- Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026 • GlobeNewswire Inc. • 04/29/2026 12:19:00 PM
- Biomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway • GlobeNewswire Inc. • 04/16/2026 12:19:00 PM
- Biomerica Launches inFoods® IBS in Canada Through Partnerships with Phoenix Airmid Biomedical and CanAlt Health Labs • GlobeNewswire Inc. • 04/14/2026 12:19:00 PM
- Biomerica Reports Third Quarter Fiscal 2026 Financial Results • GlobeNewswire Inc. • 04/13/2026 10:57:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/13/2026 09:15:20 PM
- Biomerica Receives First Commercial Order for its H. pylori test (Hp Detect™) from One of the Largest Clinical Laboratory Chains in Europe • GlobeNewswire Inc. • 03/18/2026 12:19:00 PM
- Biomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain • GlobeNewswire Inc. • 03/05/2026 01:19:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2026 10:15:26 PM
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy • GlobeNewswire Inc. • 02/26/2026 01:19:00 PM
- Vietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution • GlobeNewswire Inc. • 02/18/2026 01:19:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/28/2026 10:40:25 PM
- Biomerica Reports Second Quarter Fiscal 2026 Financial Results • GlobeNewswire Inc. • 01/14/2026 10:17:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/14/2026 10:15:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/31/2025 10:10:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/31/2025 10:10:03 PM
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test • GlobeNewswire Inc. • 12/23/2025 01:19:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/16/2025 01:19:33 PM
- Egyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio • GlobeNewswire Inc. • 12/11/2025 01:08:00 PM
- Biomerica’s inFoods® IBS Product Featured in Biotherapeutics Quarterly, a Henry Schein Publication, Highlighting a New Precision Approach for Treating IBS • GlobeNewswire Inc. • 11/25/2025 01:19:00 PM
- Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand • GlobeNewswire Inc. • 11/06/2025 01:19:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/23/2025 08:15:04 PM
- Henry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S. • GlobeNewswire Inc. • 10/16/2025 12:19:00 PM
- Biomerica Reports First Quarter Fiscal 2026 Financial Results • GlobeNewswire Inc. • 10/15/2025 01:27:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/14/2025 09:11:06 PM
